Evaluation of adrenaline auto-injector prescription profiles: A population-based, retrospective cohort study within the National Insurance Claims Database of Japan
Evaluation of adrenaline auto-injector prescription profiles: A population-based, retrospective cohort study within the National Insurance Claims Database of Japan
复制标题
肾上腺素自动注射器处方概况的评估：日本国家保险索赔数据库中基于人群的回顾性队列研究
DOI：
10.1016/j.alit.2022.02.002
复制
发表时间：
2022
影响因子：
6.8
通讯作者：
Tamari Ma
中科院分区：
文献类型：
--
作者：
Sato Sakura;Kainuma Keigo;Noda Tatsuya;Ebisawa Motohiro;Futamura Masaki;Imamura Tomoaki;Miyagawa Akihiro;Nakajima Saeko;Ogawa Yasushi;Inomata Takenori;Kan-o Keiko;Kurashima Yosuke;Masaki Katsunori;Myojin Tomoya;Nishioka Yuichi;Sakashita Masafumi;Tamari Ma
背景：肾上腺素是治疗过敏反应的一线药物。更好地了解肾上腺素自动注射器(AAI)的处方趋势对于改善患者护理以及有关健康教育干预和医疗指南的信息非常重要。然而，很难以可持续的方式收集全面的数据。因此，我们旨在调查日本AAI处方的发展趋势。方法：我们搜索了日本国家健康保险理赔和特定健康检查数据库(NDB)，这是一个独特而全面的健康保险理赔数据库，并调查了所有年龄段(2017年4月至2018年3月)的AAI处方。结果：共有88,039名受试者(56,109名男性，31,930名女性)和116,758台设备(每个患者每年1.33个AAI)至少每年开一次AAI。抗逆转录病毒药物处方率为每10万人年69.5。278.9-9岁的患者按每100,000人口年278.9的比率开出AAIs。0-19岁的患者服用AAIs的可能性是20岁以上患者的6.4倍。除20-24岁年龄组外，在所有年龄组中，男性服用AAIs的频率均高于女性。我们还评估了不同地理区域处方率的差异。结论：这一综合评估揭示了AAI处方的趋势，从而有助于制定日本关于过敏反应的预防策略。
Background: Adrenaline is the first-line medication for managing anaphylaxis. A better understanding of prescription trends for adrenaline auto-injectors (AAIs) is important to improving patient care as well as information on health education interventions and medical guidelines. However, it has been difficult to gather comprehensive data in a sustainable manner. Thus, we aimed to investigate trends in AAI prescriptions in Japan.Methods: We searched the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), a unique and comprehensive database of health insurance claims, and investigated prescriptions for AAIs for all ages (April 2017 to March 2018). We assessed the annual number of prescriptions per person as well as prescription rates per 100,000 population per year by age, sex, and geographic region.Results: A total of 88,039 subjects (56,109 males, 31,930 female) and 116,758 devices (1.33 AAIs per patient per year) were prescribed AAIs at least once a year for all ages. The prescription rate for AAIs was 69.5 per 100,000 population-years. Patients aged 0-9 years were prescribed AAIs at the rate of 278.9 per 100,000 population-years. Patients aged 0-19 years were 6.4 times more likely to be prescribed AAIs than those over 20 years of age. Males were more frequently prescribed AAIs than females in all age groups, except for those aged 20-24 years. We also evaluated differences in prescription rates by geographic region.Conclusions: This comprehensive evaluation revealed trends in AAI prescriptions, thus helping develop preventive strategies with respect to anaphylaxis in Japan.